News • COVID-19 in radiology

CT outperforms lab diagnosis for coronavirus infection

Study from China shows computed tomography of chest demonstrates better sensitivity than RT-PCR technique

In a study of more than 1,000 patients published in Radiology, chest CT outperformed lab testing in the diagnosis of 2019 novel coronavirus disease (COVID-19). Researchers at Tongji Hospital in Wuhan, China, concluded that CT should be used as the primary screening tool for COVID-19.

chest ct scan
High-resolution CT of coronal planes of a normal thorax of a 37 year old man

In the absence of specific therapeutic drugs or vaccines for COVID-19, it is essential to detect the disease at an early stage and immediately isolate an infected patient from the healthy population. According to the latest guidelines published by the Chinese government, the diagnosis of COVID-19 must be confirmed by reverse-transcription polymerase chain reaction (RT-PCR) or gene sequencing for respiratory or blood specimens, as the key indicator for hospitalization. However, with limitations of sample collection and transportation, as well as kit performance, the total positive rate of RT-PCR for throat swab samples has been reported to be about 30% to 60% at initial presentation.

Compared to RT-PCR, chest CT imaging may be a more reliable, practical and rapid method to diagnose and assess COVID-19, especially in the epidemic area

In the current public health emergency, the low sensitivity of RT-PCR implies that a large number of COVID-19 patients won’t be identified quickly and may not receive appropriate treatment. In addition, given the highly contagious nature of the virus, they carry a risk of infecting a larger population. “Early diagnosis of COVID-19 is crucial for disease treatment and control. Compared to RT-PCR, chest CT imaging may be a more reliable, practical and rapid method to diagnose and assess COVID-19, especially in the epidemic area,” the authors wrote.

Recent research found that the sensitivity of CT for COVID-19 infection was 98% compared to RT-PCR sensitivity of 71%. For the current study, researchers set out to investigate the diagnostic value and consistency of chest CT imaging in comparison to RT-PCR assay in COVID-19.

Included in the study were 1,014 patients who underwent both chest CT and RT-PCR tests between January 6 and February 6, 2020. With RT-PCR as reference standard, the performance of chest CT in diagnosing COVID-19 was assessed. For patients with multiple RT-PCR assays, the dynamic conversion of RT-PCR test results was also analyzed as compared with serial chest CT scans.

The results showed that 601 patients (59%) had positive RT-PCR results, and 888 (88%) had positive chest CT scans. The sensitivity of chest CT in suggesting COVID-19 was 97%, based on positive RT-PCR results. In patients with negative RT-PCR results, 75% (308 of 413 patients) had positive chest CT findings. Of these, 48% were considered as highly likely cases, with 33% as probable cases. By analysis of serial RT-PCR assays and CT scans, the interval between the initial negative to positive RT-PCR results was 4 to 8 days. “About 81% of the patients with negative RT-PCR results but positive chest CT scans were re-classified as highly likely or probable cases with COVID-19, by the comprehensive analysis of clinical symptoms, typical CT manifestations and dynamic CT follow-ups,” the authors wrote.


Source: Radiological Society of North America (RSNA)

28.02.2020

Read all latest stories

Related articles

Photo

News • Adaptable for screening

An optical methodology for rapid detection of COVID-19

The tool has made it possible to detect SARS-CoV-2 in exudate from symptomatic patients with a sensitivity of 100% and a specificity of 87.5%

Photo

Article • Lung cancer early diagnosis

Can we afford not to offer lung screening?

For lung cancer patients, life expectancy has hardly improved since 1970. A ten-year survival is 5%, making this the leading cause of death among all cancers. One reason is that, in most cases, the…

Photo

Article • Imaging biomarkers, AI support and beyond

New tools for Covid-19 assessment

As knowledge about Covid-19 advances, so does the arsenal of techniques to predict, diagnose and follow up on the disease. At this year’s ECR, researchers presented a range of promising imaging…

Related products

Sarstedt - COVID-19 virus diagnostics products

Saliva Collection

Sarstedt - COVID-19 virus diagnostics products

SARSTEDT AG & CO. KG
Associates of Cape Cod – Fungitell STAT Assay

Identification/Susceptibility

Associates of Cape Cod – Fungitell STAT Assay

Associates of Cape Cod Europe GmbH
Lifotronic - FA-160 Immunofluorescence Analyzer

Immunoassays

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
MinFound – ScintCare CT128

Volume CT

MinFound – ScintCare CT128

MinFound Medical Systems Co., Ltd
Nexus/Chili – Diagnost

Reading

Nexus/Chili – Diagnost

Nexus/Chili GmbH
Subscribe to Newsletter